Oral Delivery of Proteins and Peptides: Concepts and Applications - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 522

[169] Bernkop-Schnürch A, Pasta M. Intestinal peptide and protein delivery: novel
bioadhesive drug-carrier matrix shielding from enzymatic attack. J Pharm Sci 1998;87:
430-4.
[170] Bremecker KD, Stremple H, Klein G. Novel concept for a mucosal adhesive ointment.
J Pharm Sci 1984;73:548-52.
[171] Gomez-Orellana I, Paton DR. Advances in the oral delivery of proteins. Expert Opin
Ther Pat 1998;8:223-34.
[172] Hayashi M. Strategies to improve intestinal membrane transport of poorly absorbed
drugs and peptidesCurrent status on targeted drug delivery to the gastrointestinal tract.
Greenwood, SC: Capsugel Symposia Series; 1993. p. 153-60.
[173] Ganem-Quintanar A, Kalia YN, Falson-Rieg F, Buri P. Mechanism of oral permeation
enhancer. Int J Pharm 1997;156:127-42.
[174] Nakada Y, Awata N, Nakamichi C, Sugimoto I. The effects of additives on the oral
mucosal absorption of human calcitonin in rats. J Pharmacobio-Dyn 1988;11:395-401.
[175] Oh CK, Ritschel WA. Absorption characteristics of insulin through the buccal mucosa.
Methods Find Exp Clin Pharmacol 1990;12:275-9.
[176] Anderberg EK, Artursson P. Epithelial transport of drugs in cell culture. 8. Effects of
sodium dodecyl sulfate on cell membrane and tight junction permeability in human
intestinal epithelial (CACO-2) cells. J Pharm Sci 1993;82:392-8.
[177] Ziv E, Kidron M, Berry EM, Bar-On H. Bile salts promote the absorption of insulin
from the rat colon. Life Sci 1981;29:803-9.
[178] Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction
regulation. J Control Release 1994;29:253-67.
[179] Hastewell J, Lynch S, Fox R, Williamson I, Skelton-Stroud P, Mackay M.
Enhancement of human calcitonin absorption across the rat colon in vivo. Int J Pharm
1994;101:115-20.
[180] Takada K, Nakahigashi Y, Tanaka T, Kishimoto S, Ushirogawa Y, Takaya T.
Pharmacological activity of tablets containing recombinant human granulocyte colony-
stimulating factor (rhG-CSF) in rats. Int J Pharm 1994;101:89-96.
[181] Takaya T, Niwa K, Takada K. Pharmacological effect of recombinant human colony-
stimulating factor (rhG-CSF) after administration into rat large intestine. Int J Pharm
1994;110:47-53.
[182] Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug
Carrier Syst 1994;11:61-95.
[183] Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic bar-
rier to perorally administered therapeutic peptides and proteins. J Control Release
1998;52:1-16.
[184] Taki Y, Yamashita S, Sakane T, Nadai T, Sezaki H, Langguth P, et al. Gastrointestinal
absorption of metkephamid—quantitative evaluation of degradation and permeation.
Proc Int Symp Control Release Bioact Mater 1994;21:814-5.
[185] Friedman DI, Amidon GL. Oral absorption of peptides: influence of pH and inhibitors
on the intestinal hydrolysis of Leu-enkephalin and analogues. Pharm Res 1991;8:93-96.
[186] Bai JPF. Effects of bile salts on brush-border and cytosolic proteolytic activities of
intestinal enterocytes. Int J Pharm 1994;111:147-52.
[187] Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, et al. Effects of
various protease inhibitors on the intestinal absorption and degradation of insulin in
rats. Pharm Res 1994;11:1496-1500.
[188] Gomez-Orellana I, Paton DR. Advances in the oral delivery of proteins. Expert Opin
Ther Pat 1999;9:247-53.